Previous 10 | Next 10 |
JERSEY CITY, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a...
JERSEY CITY, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, will present new data from its ongoing FURI study of ibrexafungerp during the ...
New interim analysis of the Phase 3 CARES study showed complete or partial response in 78% of the 18 patients treated with ibrexafungerp for infections caused by Candida auris , a potentially deadly and multidrug-resistent pathogen with an outbreak recently reported at a Detroit speci...
JERSEY CITY, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the closing of its previously announced underwritten public offering of common stock, pre-funded warrants and warrants. The shares and warrants were sold at a public offering price of $3.00 p...
Gainers: Vallon Pharmaceuticals (VLON) +80%. Blueknight Energy Partners (BKEP) +38%. Moving iMage Technologies (MITQ) +37%. RISE Education Cayman (REDU) +15%. Sky Harbour Group (SKYH) +14%. GWG Holdings (GWGH) +14%. Evelo Biosciences (EVLO) +13%. Chindata Group Holdings (CD) +13%. Shattuck La...
Gainers: Vallon Pharmaceuticals (VLON) +84%. Shattuck Labs (STTK) +12%. Establishment Labs (ESTA) +11%. INVO Bioscience (INVO) +5%. Novan (NOVN) +5%. Losers: Babylon Holdings (BBLN) -41%. SCYNEXIS (SCYX) -25%. Clarus Therapeutics (CRXT) -16%. HCA H...
SCYNEXIS (NASDAQ:SCYX) slumps 17.2% premarket after it priced its earlier announced underwritten public offering of 3.33M shares of its common stock, prefunded warrants to purchase 11.67M shares of common stock and warrants to purchase an aggregate of 15M shares ...
Scynexis (NASDAQ:SCYX) said interim data from two ongoing phase 3 studies of oral ibrexafungerp showed improvement in ~61% of patients with fungal infection. Data from 131 patients — 113 patients in the phase 3 trial called FURI and 18 patients from the phase 3 study, dubbed CARES...
JERSEY CITY, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the pricing of its underwritten public offering of common stock, pre-funded warrants and warrants. The shares and warrants are being sold at a public offering price of $3.00 per share and acc...
Data reinforce findings from previous analyses demonstrating oral ibrexafungerp’s potential to combat difficult-to-treat and refractory fungal infections in the hospital setting. Ongoing FURI and CARES studies are a key component of the SCYNEXIS strategy to build ibrexafunger...
News, Short Squeeze, Breakout and More Instantly...
JERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment un...